Loading
A phase 2 trial of Glucarpidase, Methotrexate and Leucovorin in Osteosarcoma, run by University College, London, recorded as terminated on the registry.
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? is a phase 2 interventional study registered as NCT02022358 by University College, London, with 34 participants recorded, started 2007-07 and due to reach its primary completion in 2015-06. Interventions recorded: Glucarpidase, Methotrexate, Folinic Acid. Conditions recorded: Osteosarcoma, Spindle Cell Sarcoma of Bone.
Linked to the drug Glucarpidase because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glucarpidase, Leucovorin (folinic acid), Osteosarcoma and the tag pipeline.
Shares Glucarpidase and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Leucovorin (folinic acid) and the tag pipeline.
Shares Leucovorin (folinic acid) and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/